Business

Future of Life Science Industry to be Discussed by Panel at Chamber’s Virtual Event

By |

The Charles River Regional Chamber will host a virtual panel discussion focusing on the future of the life science sector in the area, development and more. “The Value of Life Science Development and Future Impact,” will take place on Thursday, April 13, from 11 a.m. to noon via Zoom. The event is free and open to members & nonmembers. The Chamber provided the following description:

There’s been plenty of worrisome headlines about the fate of Greater Boston’s life science sector. An oversaturated real estate market? Declining stock values and IPOs?

Business

Watertown Life Science Company Cuts Staff by Over Half, Replaces CEO

By |

SQZ Biotechnologies announced a reduction of more than half the company’s staff, and appointed a new CEO after the resignation of its previous one. The company’s research focuses on cell therapies. The company based in Watertown, announced on Nov. 30, 2022, that Armon Sharei has step down from his role as chief executive officer and the Board of Directors. The Board appointed Howard Bernstein, former Chief Scientific Officer and current director, as interim CEO.

Government

Two Proposed Life Science Buildings to Go Before Planning Board

By |

A rendering of the building proposed for 490 Arsenal Way, known as Linx II. The Planning Board will consider two life science buildings proposed to go on existing biotech sites in Watertown when it meets on Wednesday, Nov. 16. The first is at 490 Arsenal Way, where Columbia Massachusetts Arsenal Office Properties LLC seeks to build a 104,000 sq. ft.

Business

Watertown Company Acquired by Major Pharmaceutical Firm

By |

The following announcement came from Novo Nordisk:

Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per share in cash, which represents a total equity value of USD 1.1bn. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead development candidate, etavopivat, is aligned with Novo Nordisk’s strategy to complement and accelerate its scientific presence and pipeline in haemoglobinopathies, a group of disorders in which there is abnormal production or structure of the haemoglobin protein in the red blood cells. “Novo Nordisk has worked for more than 40 years to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. By adding Forma’s differentiated approach to address unmet needs for patients, we are taking a step forward in enhancing our sickle cell disease pipeline,” said Ludovic Helfgott, executive vice president and head of Rare Disease at Novo Nordisk.

Business

Biotech Companies, Educators Talk About How They Can Collaborate at Life Science Panel

By |

Natalie Nigito PhotographyKatie Sherburne, human resources manager at Forma Therapeutics speaks during the Life Sciences Panel at Hosmer School. Looking on, from right to left, are: Chris Nasveschuk, senior vice president of chemistry at C4 Therapeutics, Mark Bamforth, CEO of Arranta Bio, Watertown Superintendent Dede Galdston, and Watertown K-7 Math and Science Coordinator Elizabeth Kaplan

The life science industry has discovered Watertown, with the city becoming home to a growing number of pharmaceutical, medical and other biotech companies. Recently, representatives from a few of these companies joined Watertown educators at a forum hosted by the Watertown Business Coalition. The event took place at the new Hosmer Elementary School on April 27. The groups spoke about how they collaborate, and opportunities for the future.

Around Town

Hear from Local Life Science Companies, See Watertown’s Newest School at WBC Event

By |

The Watertown Business Coalition will be presenting it second annual Life Sciences Panel and Exhibition. The event will be held at the brand new Hosmer Elementary School. The Watertown Business Coalition provided the following information:

We invite you to join us on Wednesday, April 27, from 5:30-7:45 p.m. for our second annual Life Sciences panel and exhibition. See where the life science companies located in Watertown, or soon to be located in Watertown. Get the opportunity to share more about their business and learn and interact with the local business community and Watertown residents.

Biotech

Watertown Company Developing COVID Therapy, Trying to Inspire Future Scientists

By |

Charlie BreitroseBryan Goodwin, chief biologist at Enanta Pharmaceuticals, and Watertown High School Senior Phil Centola look at a new microscope donated by the biotech company. Watertown-based Enanta Pharmaceuticals has a potential therapy for COVID-19 ready for human testing, and it also hopes to develop some future scientists with a donation to Watertown High School. On Monday morning, representatives from Enanta presented three new microscopes donated by the company to the WHS Science Department. The equipment can be hooked up to a tablet or cellphone to make it easier to see objects under magnification, and images can even be shared with other devices. The school had one of the microscopes, said Lynsey Kraemer, the district’s Science Curriculum Coordinator for Grades 8-12, but the district could not afford more.

100 Forge

9 Story Building at Arsenal Yards Fully Leased, 5 Life Science Tenants Coming 100 Forge

By |

Boylston PropertiesA rendering of what the nine-story 100 Forge building at Arsenal Yards will look like. Developers are creating 165,000 sq. ft. of space for biotech companies. The following announcement was provided by Boylston Properties:

Boylston Properties, a Boston-based developer of mixed-use destinations, today announced that 100 Forge, its 165,595 s.f. life sciences building in the heart of Arsenal Yards in Watertown, is fully leased.